Targeting MET Exon 14 Skipping Mutations in NSCLC

home / case-based-roundtable-series / targeting-met-exon-14-skipping-mutations-in-nsclc

This roundtable series assesses the use of treatments targeting MET exon 14 skipping mutations in patients with non–small cell lung cancer discussed in virtual live events.

Part 1: Challenges in Performing Biopsies and Molecular Testing in NSCLC

Part 1: Challenges in Performing Biopsies and Molecular Testing in NSCLC

Targeted Oncology Staff
November 12th 2021

At a live virtual event, Martin Dietrich, MD, PhD, discusses how to approach biopsies and molecular testing in coordination with pathologists and testing services for patients with non–small cell lung cancer.

Tepotinib Effective for MET+ NSCLC Found by Tissue or Liquid Biopsy

Tepotinib Effective for MET+ NSCLC Found by Tissue or Liquid Biopsy

Giuseppe Giaccone, MD, PhD
November 15th 2021

Giuseppe Giaccone, MD, PhD, discusses the results of the VISION trial of tepotinib in patients with non–small cell lung cancer.

Part 2: Choosing a Treatment for NSCLC with MET Exon 14 Skipping Mutation

Part 2: Choosing a Treatment for NSCLC with MET Exon 14 Skipping Mutation

Targeted Oncology Staff
November 17th 2021

At a live virtual event, Martin Dietrich, MD, PhD, discusses treatment options for a patient with non–small cell lung cancer when molecular testing shows a MET exon 14 skipping mutation.

Part 3: Addressing Toxicities in MET Inhibitors for NSCLC

Part 3: Addressing Toxicities in MET Inhibitors for NSCLC

Targeted Oncology Staff
November 19th 2021

During a live virtual event, Martin Dietrich, MD, PhD, discusses management of toxicities and adverse events of MET inhibitors in non–small cell lung cancer.

Part 4: Whether to Switch Treatments After Discovery of MET Mutations in NSCLC

Part 4: Whether to Switch Treatments After Discovery of MET Mutations in NSCLC

Targeted Oncology Staff
November 23rd 2021

During a live virtual event, Martin Dietrich, MD, PhD, discusses how to address switching treatments in response to detection of a MET gene biomarker.

The Relevance of MET Alterations to Targeted NSCLC Therapies

The Relevance of MET Alterations to Targeted NSCLC Therapies

Martin Dietrich, MD, PhD
November 25th 2021

Martin Dietrich, MD, PhD, discusses the role MET alterations play as oncogenic drivers of non–small cell lung cancer.

Characteristics of the MET Exon 14 Skipping Mutation NSCLC Population

Characteristics of the MET Exon 14 Skipping Mutation NSCLC Population

Mark A. Socinski, MD
December 1st 2021

Mark A. Socinski, MD, discusses the patient population of the trials targeting MET exon 14 skipping mutations in non–small cell lung cancer.

Overview of MET Amplification and MET Exon 14 Skipping Mutations in NSCLC

Overview of MET Amplification and MET Exon 14 Skipping Mutations in NSCLC

Giuseppe Giaccone, MD, PhD
December 7th 2021

Giuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.

Part 1: Practices for Molecular Testing to Determine Frontline Therapy in NSCLC

Part 1: Practices for Molecular Testing to Determine Frontline Therapy in NSCLC

Targeted Oncology Staff
December 10th 2021

During a live virtual event, Ravi Salgia, MD, PhD, discussed a possible approach for biopsy and molecular testing of a patient diagnosed with lung adenocarcinoma.

Part 2: Rare Mutations and Non-Clinical Barriers for Molecular Testing in NSCLC

Part 2: Rare Mutations and Non-Clinical Barriers for Molecular Testing in NSCLC

Targeted Oncology Staff
December 16th 2021

During a live virtual event, Ravi Salgia, MD, PhD, discussed issues with molecular testing and biopsies including delays and affordability, plus identifying and responding to rare mutations detected by molecular testing.

Part 3: Factors in Using MET Inhibitors and When to Switch Inhibitors in NSCLC

Part 3: Factors in Using MET Inhibitors and When to Switch Inhibitors in NSCLC

Targeted Oncology Staff
December 28th 2021

During a live virtual event, Ravi Salgia, MD, PhD, discussed how to decide whether to use a MET inhibitor in the first line and whether to switch to a MET inhibitor from other treatments.

Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLC

Challenges for Following NCCN Guidelines for MET Inhibitors in NSCLC

Martin Dietrich, MD, PhD
January 3rd 2022

Martin Dietrich, MD, PhD, discusses the National Comprehensive Cancer Network guidelines for using MET inhibitors in patients with non–small cell lung cancer and their impact on sequencing therapies.

VISION Trial Shows Favorable Tolerability of Tepotinib in NSCLC

VISION Trial Shows Favorable Tolerability of Tepotinib in NSCLC

Mark A. Socinski, MD
January 17th 2022

Mark A. Socinski, MD, discusses the safety profile of tepotinib that was observed in the VISION trial of patients with advanced or metastatic non–small cell lung cancer with MET exon 14 skipping mutations.